Product IntroductionBioactivity英文名:
Roflumilast描述: Roflumilast (APTA 2217) 是一种口服的长效 4 型磷酸二酯酶抑制剂 (PDE4),具有抗炎和潜在的抗肿瘤活性,作用于PDE4A1,PDEA4,PDEB1和PDEB2,IC50分别为 0.7,0.9,0.7 和 0.2 nM。
激酶实验: PDE activity is determined with some modifications. The assay mixture contain 50 mM Tris (pH 7.4), 5 mM MgCl2, 0.5 μM cAMP or cGMP, and [3H]cAMP or [3H]cGMP (about 30,000 cpm/assay), the indicated concentration of the inhibitor and an aliquot of the enzyme solution at a final assay volume of 200 μL. Stock solutions of the compounds are diluted 1:100 (v/v) in the Tris buffer mentioned above; appropriate dilutions are prepared in 1% (v/v) DMSO/Tris buffer, which are diluted 1:2 (v/v) in the assays to obtain the desired final concentrations of the inhibitors at a DMSO concentration of 0.5% (v/v). DMSO itself affected none of the PDE activities. After preincubation for 5 min at 37°C, the reaction is started by the addition of substrate (cAMP or cGMP) and the assays are incubated for further 15 min at 37°C. Then 50 μL of 0.2 N HCl is added to stop the reaction and the assays are left on ice for about 10 min. Following incubation with 25 μg of 5′-nucleotidase (Crotalus atrox snake venom) for 10 min at 37°C, the assays are loaded on QAE Sephadex A-25 (1 mL of bed volume in Poly-Prep chromatography columns). The columns are eluted with 2 mL of 30 mM ammonium formate (pH 6.0) and the eluate is counted for radioactivity. Results are corrected for blank values (measured in the presence of denatured protein) that are below 5% of total radioactivity. The amount of cyclic nucleotides hydrolyzed did not exceed 30% of the original substrate concentration[3].
体外活性: 在体内实验中,Roflumilast使氧化压力下降.在动物模型中,Roflumilast可一定程度抵抗肺炎(COPD相关).在暴露于烟草7个月的小鼠肺中, Roflumilast(5 mg/kg/day )诱导巨噬细胞,中性粒细胞,B细胞,树突状细胞,CD8+ T细胞,CD4+ T 细胞分别减少82%,78%,100%, 48%,88%和98%.博来霉素气管内给药14天后,Roflumilast(5 mg/kg/day )可适度降低小鼠BAL体液中过氧化氢脂质的增高.在博来霉素处理以后,Roflumilast剂量依赖性降低肺部总羟脯氨酸含量,5 mg/kg/day可抑制47%,并降低肺部纤维化损伤和αI(I)胶原蛋白转录.
体内活性: 在体外实验中,Roflumilast起免疫调节和抗炎活性作用。Rolfumilast对抗CD28和CD3抗体激活的CD4+ T细胞具有抑制作用(IC30:7 nM),且分别对IL-2(IC20:1 nM),IL-4(IC30:7 nM),IL-5(IC25:13 nM),以及 IFN-v(IC35:8 nM)的合成有抑制作用。在人类嗜中性粒细胞中,Roflumilast抑制LTB4合成(IC50:2 nM)。在酸性粒细胞和中性粒细胞中,Roflumilast对fMLP刺激的ROS形成有抑制作用,IC35 分别是7 nM和4 nM。在单核细胞中,Roflumilast对脂多糖诱导的TNF-α合成有抑制作用(IC40:21 nM)。在源于单核细胞的树突状细胞中,Roflumilast对脂多糖诱导的TNF-α合成有抑制效果(IC20: 5 nM)。
存储条件: Powder: -20°C for 3 years | In solvent: -80°C for 1 year
溶解度: H2O : < 1 mg/mL (insoluble or slightly soluble)
Ethanol : 12 mg/mL (29.8 mM)
DMSO : 50 mg/mL (124 mM)
关键字:
BY217 |
Respiratory syncytial virus |
BYK20869 |
RSV |
Phosphodiesterase (PDE) |
BY-217 |
inhibit |
APTA2217 |
Inhibitor |
APTA-2217 |
BYK-20869 |
Roflumilast相关产品:
BW-A 78U |
Lirimilast |
Siguazodan |
Milrinone |
PDE7-IN-2 |
MR-L2 |
Ensifentrine |
RS-25344 hydrochloride |
Olprinone |
Z-HA155相关库:
Anti-Neurodegenerative Disease Compound Library |
Drug Repurposing Compound Library |
Anti-Cancer Drug Library |
Inhibitor Library |
Anti-Cancer Clinical Compound Library |
Pediatric Drug Library |
Anti-Cancer Active Compound Library |
Anti-Cancer Approved Drug Library |
EMA Approved Drug Library |
Anti-Infection Compound Library